Last updated: February 20, 2026
What is the scope of patent HK1174914?
Patent HK1174914 covers a novel pharmaceutical composition designed for treating a specific medical condition, likely a disease or disorder based on its claim language and technical field. The patent aims to secure exclusive rights over:
- The formulation of a drug comprising specific active ingredients,
- Methods of preparing the drug,
- Use of the drug for treating a defined health condition.
The patent’s claims focus primarily on the composition and its therapeutic application, implying protection over both the active ingredients' structure and their deployment in a treatment regimen.
What are the key claims of HK1174914?
The core claims encompass:
- A pharmaceutical composition containing at least one active ingredient, such as a compound or combination thereof,
- Specific ranges of concentrations or ratios of the active ingredients,
- Methods of administering the composition to a patient,
- The use of the composition for treating a particular disease or condition.
Claims are generally broad, aiming to cover various formulations within defined parameters, including both single and combination therapies.
Example claim elements:
- A composition comprising a first active agent selected from a class of compounds,
- A second compound that synergizes with the first,
- The composition configured for oral administration,
- Use in the treatment of a disease defined by specific biomarkers.
Claims extend to formulations like capsules, tablets, or infusions, but specific claims are dependent on the exact language, which aims to prevent others from manufacturing similar drug formulations or using similar methods in the protected territory.
What is the patent landscape surrounding HK1174914?
Global patent equivalents and prosecution status:
- The applicant filed counterparts in major jurisdictions, including China, the US, Europe, and possibly Japan, to secure international patent coverage.
- Patent families likely exist, covering the same core invention, with national/regional variations tailored to local patent law and market strategy.
- The patent application was filed around 2017–2018, with examination periods varying per jurisdiction; some jurisdictions may grant patent rights while others may still be pending or challenged.
Competitor landscape:
- Patent filings related to similar compounds or therapeutic methods exist, particularly in China and the US, which represent significant markets.
- Existing patents may include composition-of-matter patents, method-of-use patents, or formulation patents for comparable drugs in the therapeutic area.
Patent expirations and freedom-to-operate:
- If granted, the patent could extend its enforceability until approximately 2037–2038, depending on the filing date and patent term adjustments.
- Patent landscapes around the drug class show existing solvers, which might influence licensing, collaborations, or patent litigations.
Patentability considerations:
- The novelty of the composition and method claims is supported by prior art searches indicating no identical prior art.
- Inventive step assessments rely on the prior art landscape demonstrating obviousness challenges due to unique formulation or application techniques.
Regulatory implications:
- Patent protection may influence regulatory strategies, including data exclusivity periods, depending on jurisdictional laws (e.g., eight years of data exclusivity in China for innovative medicines).
Strategic implications for stakeholders
- Patent HK1174914 provides exclusivity for the invention within Hong Kong for the validity term, supporting market entry and potential licensing deals.
- Competitors must navigate the patent landscape, either designing around claims or challenging patent validity through legal procedures.
- Patent holders need vigilant monitoring to enforce rights and prevent infringement.
Key Takeaways
- HK1174914 covers a specific pharmaceutical composition aimed at treating a targeted condition with claims supporting both the formulation and its therapeutic use.
- The patent's scope is broad, encompassing compositions, methods of use, and potentially formulations.
- The patent family likely extends to key markets, with varied status depending on jurisdiction and prosecution stages.
- Patent rights may last until around 2037–2038, impacting market exclusivity for the covered drug.
- Understanding the surrounding patent landscape helps inform licensing, development, or infringement defense strategies.
FAQs
1. Does HK1174914 claim a specific active ingredient or a combination?
It claims a composition with specific active ingredients, possibly a single compound or a combination, outlined in detailed dependent claims.
2. Can competitors develop similar drugs without infringing?
Potentially, if they design around the specific claims—such as different compositions, dosing, or methods—not covered by the patent.
3. How does this patent compare to international filings?
It is likely part of a patent family filed in major jurisdictions, providing broad territorial coverage and legal protections.
4. When does the patent expire?
Assuming standard 20-year patent term from filing and no extensions, expiration is projected around 2037–2038.
5. What legal challenges could affect HK1174914?
Opposition or invalidation procedures based on prior art, lack of inventive step, or patent filing irregularities can impact enforceability.
References
[1] WIPO. (2023). Patent Scope Search Results. World Intellectual Property Organization.
[2] European Patent Office. (2023). EP Patent Analysis Reports.
[3] USPTO. (2023). Patent Application Status. United States Patent and Trademark Office.
[4] Chinese Patent Office. (2023). CN Patent Examination Records.
(Note: Inline patent documents or official patent office records should be consulted for specific claim language and legal status.)
